GlassScriptPhysician profile
Geraldine Emanuel
NPI 1023065083
$12,247.94
in general payments reported to CMS, 2019-2025
26 companies · $3,085 in 2025
The $3,085 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,532 · 2022: $2,434 · 2023: $2,383 · 2024: $2,814 · 2025: $3,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,824 · Education: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,824.31 |
| Education | $457.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,567.30 | 2021-2025 | |
| Janssen Biotech, INC. | $2,181.54 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $1,133.84 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $907.85 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $864.78 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Incyte Corporation | $651.93 | 2021-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $581.05 | 2021-2025 | |
| Lilly USA, LLC | $502.18 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $478.17 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $390.02 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $349.79 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $307.47 | 2022-2024 | Vtama |
| Organon LLC | $297.92 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $279.26 | 2021-2025 | |
| Galderma Laboratories, L.P. | $174.77 | 2024-2025 | Nemluvio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $154.72 | 2021-2025 | Otezla |
| Janssen Scientific Affairs, LLC | $105.45 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Lnhc, INC | $58.99 | 2025 | Zelsuvmi |
| Smith+Nephew, INC. | $38.17 | 2023 | Grafix Pl |
| Almirall LLC | $27.74 | 2022 | |
| Mayne Pharma Commercial LLC | $21.72 | 2025 | |
| Verrica Pharmaceuticals INC. | $20.28 | 2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $18.81 | 2021 | |
| Arcutis Biotherapeutics, INC. | $17.46 | 2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.74 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geraldine Emanuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.